A multi-country, multi-centre, observational, retrospective study to revealthe patient characteristics, disease burden, treatment patterns and patientjourney of stage III non-small-cell lung cancer patients

AstraZeneca Pharma India Limited0 个研究点目标入组 494 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•1. Provision of informed consent by the patient or next of kin/legal representative (for deceased patients at study entry, unless a waiver was granted), according to local regulations
•2. Adult male or female (18 years old or according to age of majority as defined by local regulations)
•3. First ever diagnosis of lung cancer (absence of previous diagnosis of lung cancer, including small cell lung cancer [SCLC] and NSCLC) in the patientÃ¢â?¬•s medical records
•4. Primary diagnosis of stage III NSCLC, confirmed by pathology, between 01 January 2013 and 31 December 2017
•5. Available medical records at the participating site reflect at least 9 months of follow-up from the index date (unless patient died within the first 9 months of diagnosis)

•1. Patients with a concomitant cancer at the time of diagnosis of stage III NSCLC, except for non-metastatic non-melanoma skin cancers or in situ or benign neoplasms. A cancer will be considered concomitant if it occurs within 5 years of NSCLC diagnosis
•2. Patients initially diagnosed with stage I-II NSCLC who have progressed to stage III

发起方